Novartis punts a late-stage PI3K drug with a worrying safety profile to one of China’s upstart biotechs
Just months after a group of researchers warned against the further development of a worrying PI3K inhibitor project Novartis had been working on, the pharma …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.